253- Sarafidis PA. Epidemiology of resistant hypertension. J Clin Hypertens (Greenwich).
2011;13:523–8. - Sarafidis PA, Georgianos P, Bakris GL, et al. Resistant hypertension—its identification and
epidemiology. Nat Rev Nephrol. 2013;9:51–8. - Calhoun DA. Apparent and true resistant hypertension: why not the same? J Am Soc
Hypertens. 2013;7(6):509–11. - World Health Organization. The world health report – reducing risks, promoting healthy life.
(2002). http://www.who.int/whr/2002/en (Version current at April 26, 2006). - Wagner EH, Davis C, Schaefer J, et al. A survey of leading chronic disease management
programs: are they consistent with the literature? Manag Care Q. 1999;7:56–66. - The WHIC Chronic Disease Management (CDM) Infostructure Initiative. 2006. http://www.whic.
org/public/profiles/cdm.html (Version current at April 26, 2006). - Canadian Hypertension Education Program. 2006. http://www.hypertension.ca/CHEP2006/
CHEP_2006_complete.pdf (Version current at May 9, 2006). - Haynes RB, Sackett DL, Gibson ES, et al. Improvement of medication compliance in uncon-
trolled hypertension. Lancet. 1976;1:1265–8. - Ashida T, Yokoyama S, Ebihara A, et al. Profiles of patients who control the doses of
their antihypertensive drugs by self-monitoring of home blood pressure. Hypertens Res.
2001;24:203–7. - Moser M, Setaro JF. Clinical practice. Resistant or difficult-to-control hypertension. N Engl
J Med. 2006;355(4):385–92. - Pimenta E, Calhoun DA, Oparil S. Mechanisms and treatment of resistant hypertension.Arq.
Bras Cardiol. 2007;88(6):683–92. - Makris A, Seferou M, Papadopoulos DP. Resistant hypertension workup and approach to
treatment. Int J Hypertens. 2010;2011:598694. - Pimenta E, Calhoun DA. Resistant hypertension: incidence, prevalence, and prognosis.
Circulation. 2012;125(13):1594–6. - Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension
in hypertensive patients. Circulation. 2012;125(13):1635–42. - Khan TV, Khan SS, Akhondi A, et al. White coat hypertension: relevance to clinical and
emergency medical services personnel. Med Gen Med. 2007;9(1):52. - Oliveira-Filho AD, Barreto-Filho JA, Neves SJ, et al. Association between the 8-item
Morisky medication adherence scale (MMAS-8) and blood pressure control. Arq Bras
Cardiol. 2012;99(1):649–58. - Morisky DE, Ang A, Krousel-Wood M, et al. Predictive validity of a medication adherence
measure in an outpatient setting. J ClinHypertens (Greenwich). 2008;10(5):348–54. - Maurer H, Pfleger K. Identification and differentiation of beta-blockers and their metabo-
lites in urine by computerized gas chromatography mass spectrometry. J Chromatogr.
1986;382:147–65. - Maurer HH. Systematic toxicological analysis procedures for acidic drugs and/or metabolites
relevant to clinical and forensic toxicology and/or doping control. J Chromatogr B Biomed
Sci Appl. 1999;733:3–25. - Maurer HH. Perspectives of liquid chromatography coupled to lowand high-resolution mass
spectrometry for screening, identification, and quantification of drugs in clinical and forensic
toxicology. Ther Drug Monit. 2010;32:324–7. - Ojanpera L, Pelander A, Laks S, et al. Application of accurate mass measurement to urine
drug screening. J Anal Toxicol. 2005;29:34–40. - Maurer HH, Tenberken O, Kratzsch C, et al. Screening for library-assisted identification
and fully validated quantification of 22 beta-blockers in blood plasma by liquid chromatog-
raphymass spectrometry with atmospheric pressure chemical ionization. J Chromatogr A.
2004;1058:169–81. - Kristoffersen L, Øiestad EL, Opdal MS, et al. Simultaneous determination of 6 beta-blockers,
3 calcium-channel antagonists, 4 angiotensin-II antagonists and 1 antiarrhythmic drug in
15 Public Health Efforts for Earlier Resistant Hypertension Diagnosis...